Aiosyn Launches Kidney Image Analysis Services Through Its NephroPath Platform to Accelerate Drug Development Studies
Aiosyn , a pioneering medical software company specializing in AI-powered pathology solutions for cancer and kidney disease, announced the introduction of its NephroPath platform .
- Aiosyn , a pioneering medical software company specializing in AI-powered pathology solutions for cancer and kidney disease, announced the introduction of its NephroPath platform .
- By partnering with Aiosyn, CROs, biopharma, and researchers can accelerate the development of Chronic Kidney Disease (CKD) therapies using new and quantitative insights offered through Nephropath’s Kidney Image Analysis Services .
- Through Nephropath’s Kidney Image Analysis Services, Aiosyn offers whole kidney quantification and custom kidney analyses.
- “Using Aiosyn's NephroPath platform we provide researchers with a new and powerful technique to complement the CKD drug development toolbox,” said Patrick de Boer, CEO of Aiosyn.